EA200400305A1 - 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность - Google Patents

2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность

Info

Publication number
EA200400305A1
EA200400305A1 EA200400305A EA200400305A EA200400305A1 EA 200400305 A1 EA200400305 A1 EA 200400305A1 EA 200400305 A EA200400305 A EA 200400305A EA 200400305 A EA200400305 A EA 200400305A EA 200400305 A1 EA200400305 A1 EA 200400305A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
aminocarbonyl
mono
amino
optionally substituted
Prior art date
Application number
EA200400305A
Other languages
English (en)
Other versions
EA007933B1 (ru
Inventor
Кристофер Джон Лав
Жан Пьер Франс Ван Вауве
Марк Ж. Де Брабандер
Роджер Клайв Мозес
Михайло Гончаренко
Людвиг Поль Коиманс
Неле Вандермасен
Гастон Станислас Марселла Дилс
Энтони Вилльям Сиблей
Катерина Ноула
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA200400305A1 publication Critical patent/EA200400305A1/ru
Publication of EA007933B1 publication Critical patent/EA007933B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)

Abstract

Изобретение относится к применению соединения формулы (I), его N-оксида, фармацевтически приемлемой аддитивной соли, четвертичного амина и стереохимически изомерной формы, где Z представляет собой галоген; Cалкил; Cалкил, замещенный гидрокси, карбоксилом, циано, амино, моно- или ди(Cалкил)амино, аминокарбонилом, моно- или ди(Cалкил)аминокарбонилом, Cалкилоксикарбонилом или Cалкилокси; полигалоген-Cалкил; Cалкилокси; циано; амино; аминокарбонил; моно- или ди(Cалкил)аминокарбонил; Cалкилоксикарбонил; Cалкилкарбонилокси; HN-S(=O); моно- или ди (Cалкил) амино-S(=O); -C(=N-R)NRR; Q представляет собой необязательно замещенной углеродный цикл или необязательно замещенный гетероцикл; L представляет собой замещенный фенил или необязательно замещенный моноциклический 5- или 6-членный частично насыщенный или ароматический гетероцикл или бициклический частично насыщенный или ароматический гетероцикл; арил представляет собой необязательно замещенный фенил, для изготовление лекарственного средства для предотвращения или лечения заболеваний, опосредованных TNF-α и/или IL-12.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200400305A 2001-08-13 2002-08-09 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность EA007933B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01203088 2001-08-13
PCT/EP2002/008956 WO2003015776A1 (en) 2001-08-13 2002-08-09 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity

Publications (2)

Publication Number Publication Date
EA200400305A1 true EA200400305A1 (ru) 2004-08-26
EA007933B1 EA007933B1 (ru) 2007-02-27

Family

ID=8180791

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400305A EA007933B1 (ru) 2001-08-13 2002-08-09 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность

Country Status (26)

Country Link
US (1) US7138403B2 (ru)
EP (1) EP1418911B1 (ru)
JP (1) JP4491231B2 (ru)
KR (1) KR100922538B1 (ru)
CN (1) CN100502863C (ru)
AR (1) AR037232A1 (ru)
AT (1) ATE325608T1 (ru)
AU (1) AU2002331227B2 (ru)
BR (1) BR0211910A (ru)
CA (1) CA2451981C (ru)
DE (1) DE60211348T2 (ru)
EA (1) EA007933B1 (ru)
ES (1) ES2264734T3 (ru)
HK (1) HK1077507A1 (ru)
HR (1) HRP20040098B1 (ru)
HU (1) HUP0401160A3 (ru)
IL (2) IL160327A0 (ru)
MX (1) MXPA04001400A (ru)
MY (1) MY130780A (ru)
NO (1) NO327345B1 (ru)
NZ (1) NZ530772A (ru)
PL (1) PL210475B1 (ru)
TW (1) TWI268152B (ru)
UA (1) UA79756C2 (ru)
WO (1) WO2003015776A1 (ru)
ZA (1) ZA200401164B (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
JP2007519720A (ja) 2004-01-28 2007-07-19 スミスクライン ビーチャム コーポレーション チアゾール化合物
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
JP2008516946A (ja) * 2004-10-15 2008-05-22 アストラゼネカ・アクチエボラーグ 置換されたアミノ−ピリミドンおよびそれらの使用
JP2008516945A (ja) * 2004-10-15 2008-05-22 アストラゼネカ・アクチエボラーグ 置換されたアミノ化合物およびそれらの使用
JP2008531537A (ja) * 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド 化合物
BRPI0616655A2 (pt) 2005-10-03 2011-06-28 Ono Pharmaceutical Co composto heterocìclico contendo nitrogênio e aplicação farmacêutica do mesmo
RU2010121969A (ru) * 2007-11-01 2011-12-10 Актелион Фармасьютиклз Лтд (Ch) Новые производные пиримидина
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
TWI403506B (zh) * 2008-06-16 2013-08-01 Faes Farma Sa 用於治療急性和慢性發炎疾病之５－（４－甲磺醯基－苯基）－噻唑衍生物類
ES2426953T3 (es) 2008-07-17 2013-10-28 Bayer Cropscience Ag Compuestos heterocíclicos como pesticidas
KR101406433B1 (ko) 2008-09-22 2014-06-13 카이맨 케미칼 컴파니 인코포레이티드 Ｈ-ｐｇｄｓ 억제제로서 다중헤테로아릴 화합물 및 프로스타글란딘 ｄ2 매개된 질병의 치료를 위한 그의 용도
TW201026693A (en) * 2008-10-01 2010-07-16 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
CN101391984B (zh) * 2008-11-07 2010-12-08 东华大学 碳酸二甲酯对含巯基的嘧啶杂环化合物进行甲基化的方法
US9090601B2 (en) * 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2011138285A1 (de) 2010-05-05 2011-11-10 Bayer Cropscience Ag Thiazolderivate als schädlingsbekämpfungsmittel
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CA2807971A1 (en) 2010-08-11 2012-02-16 Millenium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
UY33671A (es) 2010-10-13 2012-04-30 Millenium Pharmaceuticals Inc Heteroarilos y sus usos
US20120129843A1 (en) * 2010-11-18 2012-05-24 Yan Zhang Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
WO2012109573A1 (en) * 2011-02-11 2012-08-16 Purdue Research Foundation Substituted thiazoles for use as antiviral agents
CN104603124B (zh) 2012-08-10 2018-04-17 勃林格殷格翰国际有限公司 用作布鲁顿酪氨酸激酶(btk)抑制剂的杂芳族化合物
BR112015009751A2 (pt) * 2012-10-31 2017-07-11 Bayer Cropscience Ag novos compostos heterocíclicos como pesticidas
EP2925744B1 (en) 2012-11-27 2020-12-30 Thomas Helledays Stiftelse För Medicinsk Forskning Pyrimidine-2,4-diamine derivatives for treatment of cancer
JP6486954B2 (ja) 2014-01-29 2019-03-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害剤としてのピラゾール化合物
CA2948601A1 (en) 2014-06-04 2015-12-10 Thomas Helledays Stiftelse For Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
WO2015187088A1 (en) 2014-06-04 2015-12-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of cancer
JOP20200117A1 (ar) 2014-10-30 2017-06-16 Janssen Pharmaceutica Nv كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t
EP3212641B1 (en) 2014-10-30 2018-12-05 Janssen Pharmaceutica NV Thiazoles as modulators of roryt
CN108064224B (zh) * 2014-10-30 2022-03-29 詹森药业有限公司 作为Rorγt的调节剂的酰胺取代的噻唑
EP3390390B1 (en) 2015-12-16 2021-09-01 Boehringer Ingelheim International Gmbh Bipyrazolyl derivatives useful for the treatment of autoimmune diseases
EP3402789B1 (en) 2016-01-13 2020-03-18 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
US10414759B2 (en) * 2017-05-08 2019-09-17 Purdue Research Foundation Phenylthiazoles and uses thereof
CN112292373A (zh) 2018-06-18 2021-01-29 詹森药业有限公司 作为RORγt的调节剂的吡啶基吡唑类
US10975057B2 (en) 2018-06-18 2021-04-13 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of RORgT
CA3103929A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl substituted pyrazoles as modulators of roryt
CN112334450A (zh) 2018-06-18 2021-02-05 詹森药业有限公司 作为RORγt的调节剂的苯基和吡啶基取代的咪唑
CN110746325A (zh) * 2018-07-24 2020-02-04 上海和辉光电有限公司 一种基于胍骨架的n型掺杂化合物及其应用
CN110452224B (zh) * 2019-08-30 2022-06-03 西南大学 嘧啶唑醇类化合物及其制备方法和应用
WO2022155941A1 (en) * 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE258165C (ru)
US3499762A (en) 1966-11-03 1970-03-10 Eastman Kodak Co Photographic elements comprising novel u.v.-absorbing optical brightening agents
DE1959307A1 (de) 1969-11-26 1971-06-03 Basf Ag Optische Aufheller
BE795907A (fr) * 1972-02-25 1973-06-18 Luso Farmaco Inst 2-amino-4-arylthiazoles 5-substitues et leur preparation
US4649146A (en) 1983-01-31 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and pharmaceutical composition comprising the same
JPH03144612A (ja) 1989-10-31 1991-06-20 Nec Corp 接続方法
JPH04368375A (ja) * 1991-06-17 1992-12-21 Otsuka Pharmaceut Factory Inc イソオキサゾール誘導体
US5240929A (en) * 1992-08-03 1993-08-31 Warner-Lambert Company 2-heterocyclic-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
CA2195847A1 (en) * 1994-07-27 1996-02-08 John J. Talley Substituted thiazoles for the treatment of inflammation
AU6788996A (en) 1995-08-02 1997-02-26 J. Uriach & Cia S.A. New carboxamides with antifungal activity
AR008395A1 (es) 1996-07-09 2000-01-19 Astra Pharma Prod Compuesto derivado de pirimidina, composicion farmaceutica que lo comprende, procedimiento para prepararlo, y compuesto intermediario util parallevar a cabo dicho procedimiento.
WO1998008830A1 (de) 1996-08-26 1998-03-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazol-derivate als selektive inhibitoren der pde-iv
SI0920426T1 (en) 1996-08-26 2004-04-30 Altana Pharma Ag New thiazole derivatives with phosphodiesterase-inhibiting effect
DE69903976T2 (de) * 1998-12-16 2003-07-24 Aventis Pharma Ltd Heteroaryl-zyklische acetale
DE10001644A1 (de) * 1999-01-19 2000-07-20 Clariant Gmbh Fluorierte Azole und ihre Verwendung in flüssigkristallinen Mischungen
WO2001030778A1 (en) 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
ES2222336T3 (es) * 2000-01-18 2005-02-01 Vertex Pharma Inhibidores de girasas y sus usos.
AU3740101A (en) 2000-03-01 2001-09-12 Janssen Pharmaceutica Nv 2,4-disubstituted thiazolyl derivatives
CN100355751C (zh) * 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
GB0031109D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
JP2004517100A (ja) * 2000-12-20 2004-06-10 グラクソ　グループ　リミテッド ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール
GB0031103D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
JP4491231B2 (ja) 2010-06-30
KR20040043134A (ko) 2004-05-22
EA007933B1 (ru) 2007-02-27
AU2002331227B2 (en) 2008-01-24
EP1418911B1 (en) 2006-05-10
DE60211348T2 (de) 2007-02-08
HRP20040098A2 (en) 2004-06-30
CN1633294A (zh) 2005-06-29
MY130780A (en) 2007-07-31
TWI268152B (en) 2006-12-11
ATE325608T1 (de) 2006-06-15
HRP20040098B1 (en) 2012-08-31
UA79756C2 (en) 2007-07-25
WO2003015776A1 (en) 2003-02-27
US20040254192A1 (en) 2004-12-16
KR100922538B1 (ko) 2009-10-21
HUP0401160A2 (hu) 2004-09-28
DE60211348D1 (de) 2006-06-14
ES2264734T3 (es) 2007-01-16
CA2451981C (en) 2012-02-21
NO20040631L (no) 2004-03-12
IL160327A (en) 2010-05-17
ZA200401164B (en) 2005-07-27
AR037232A1 (es) 2004-11-03
JP2005504767A (ja) 2005-02-17
EP1418911A1 (en) 2004-05-19
NZ530772A (en) 2006-03-31
HUP0401160A3 (en) 2008-01-28
IL160327A0 (en) 2004-07-25
CN100502863C (zh) 2009-06-24
NO327345B1 (no) 2009-06-15
US7138403B2 (en) 2006-11-21
CA2451981A1 (en) 2003-02-27
PL368241A1 (en) 2005-03-21
HK1077507A1 (en) 2006-02-17
PL210475B1 (pl) 2012-01-31
MXPA04001400A (es) 2004-05-27
BR0211910A (pt) 2004-10-19

Similar Documents

Publication Publication Date Title
EA200400305A1 (ru) 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность
EA200400306A1 (ru) 2-амино-4,5-тризамещенные производные тиазолила
RU2353616C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
RU2336275C2 (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция
EA200600257A1 (ru) Производные триазолопиримидина в качестве ингибиторов киназы гликогенсинтазы-3
NO20051754L (no) Quinolylpropylpiperidinderivater, fremgangsmate for fremstilling derav og mellomprodukter og preparater inneholdende slike derivater
PE20010482A1 (es) Derivados de 3-ureido-pirazol y procedimiento para su preparacion
PE20060243A1 (es) Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina
AR033306A1 (es) Compuestos
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
PE20050664A1 (es) Derivados de 1h-imidazo[4,5-c]quinolina
NZ509318A (en) Amide derivatives, their preparation and use in the treatment of diseases mediated by cytokines
AR037682A1 (es) Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
AR047339A1 (es) Derivados de difenilazetidona.proceso de obtencion.
EA200300333A1 (ru) Новые тиадиазолы и оксадиазолы и их применение в качестве ингибиторов фосфодиэстеразы-7
BR0213660A (pt) Composto, composição farmacêutica e método para tratar pacientes
JP2013509392A5 (ru)
AR035732A1 (es) Derivados cromen-2-carboxilicos terapeuticos, uso de estos derivados para la preparacion de medicamentos, composicion farmaceutica, compuestos relacionados, y procesos para preparar estos compuestos relacionados
AR050711A1 (es) Derivados arilsulfonilestilbeno para el tratamiento y/o prevencion de afecciones del sistema nervioso central
DE60006057D1 (de) Heteroarylphenylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
UY33150A (es) Compuestos carboxamida y su uso como inhibidores v de calpaína
EA200400219A1 (ru) Производные хинолина и их использование в качестве противоопухолевых средств
EA200500298A1 (ru) 2-аминобензотиазолсульфонамидные ингибиторы протеазы вич широкого спектра действия
WO2004005256A3 (en) Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU